drugset / Trial / NCT06522945
To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQD3524 injection in patients with renal impairment after a single dose, and to evaluate the urinary excretion of the drug in these patients after a single dose, as well as to evaluate the safety of the drug in these patients after a single dose.
Timeline
- Start
- 2024-07-24
- Primary completion
- 2025-12-18
- Completion
- 2025-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TQD3524 | Unknown | 1.25 mg/kg | — |
| Comparator | TQD3524 | Unknown | 2.5 mg/kg | — |